Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 11/20 | 0.40 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | FPR1 | P21462 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5137330 | 0.95 | BCHE (0.43) | CASRBCHEC5AR1MEN1KMT2A | |
| SCHEMBL5135915 | 0.92 | BCHE (0.41) | CASRBCHEC5AR1MEN1KMT2A | |
| SCHEMBL5137301 | 0.91 | BCHE (0.45) | CASRBCHEC5AR1MEN1KMT2A | |
| SCHEMBL5137642 | 0.91 | POLB (0.37) | CASRC5AR1MAPTPOLB | |
| SCHEMBL5072348 | 0.91 | POLB (0.37) | CASRC5AR1MAPTPOLB | |
| SCHEMBL5135665 | 0.88 | CASR (0.38) | CASRBCHEC5AR1MEN1KMT2A | |
| SCHEMBL5069962 | 0.88 | BCHE (0.45) | CASRBCHEC5AR1 | |
| SCHEMBL5136715 | 0.87 | C5AR1 (0.43) | CASRBCHEC5AR1MEN1KMT2A | |
| SCHEMBL5135308 | 0.86 | C5AR1 (0.41) | C5AR1 | |
| SCHEMBL5137007 | 0.86 | DRD2 (0.38) | CASRBCHEC5AR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |